– Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –

– Findings demonstrate differentiated menin binding and activity against certain resistance-associated mutations, further supporting ziftomenib’s potential across genetically defined acute leukemias –

SAN DIEGO, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a biopharmaceutical company focused on precision medicines for cancer, today announced the publication of a manuscript in Blood, the flagship journal of the American Society of Hematology, detailing the discovery and preclinical development of ziftomenib, a potent and selective menin inhibitor approved by the U.S. Food and Drug Administration in 2025 for adult patients with relapsed or refractory NPM1-mutated acute myeloid leukemia (AML).

The publication describes the scientific foundation underlying ziftomenib’s development, including its differentiated binding profile, potent and selective inhibition of the menin-KMT2A interaction, activity across multiple genetically defined leukemia models, and activity against certain treatment-emergent MEN1 mutations associated with resistance to other menin inhibitors.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.